These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29322544)

  • 1. Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study.
    Dallio M; Masarone M; Errico S; Gravina AG; Nicolucci C; Di Sarno R; Gionti L; Tuccillo C; Persico M; Stiuso P; Diano N; Loguercio C; Federico A
    Aliment Pharmacol Ther; 2018 Mar; 47(6):826-837. PubMed ID: 29322544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease.
    Federico A; Dallio M; Gravina AG; Diano N; Errico S; Masarone M; Romeo M; Tuccillo C; Stiuso P; Morisco F; Persico M; Loguercio C
    Int J Environ Res Public Health; 2020 May; 17(10):. PubMed ID: 32408667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease.
    Dallio M; Diano N; Masarone M; Gravina AG; Patanè V; Romeo M; Di Sarno R; Errico S; Nicolucci C; Abenavoli L; Scarpellini E; Boccuto L; Persico M; Loguercio C; Federico A
    Int J Environ Res Public Health; 2019 Aug; 16(17):. PubMed ID: 31466361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review.
    Cano R; Pérez JL; Dávila LA; Ortega Á; Gómez Y; Valero-Cedeño NJ; Parra H; Manzano A; Véliz Castro TI; Albornoz MPD; Cano G; Rojas-Quintero J; Chacín M; Bermúdez V
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic Lipid Accumulation and Nrf2 Expression following Perinatal and Peripubertal Exposure to Bisphenol A in a Mouse Model of Nonalcoholic Liver Disease.
    Shimpi PC; More VR; Paranjpe M; Donepudi AC; Goodrich JM; Dolinoy DC; Rubin B; Slitt AL
    Environ Health Perspect; 2017 Aug; 125(8):087005. PubMed ID: 28796629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of bisphenol A and its analogue bisphenol S on human hepatic cells: a focus on their potential involvement in nonalcoholic fatty liver disease.
    Peyre L; Rouimi P; de Sousa G; Héliès-Toussaint C; Carré B; Barcellini S; Chagnon MC; Rahmani R
    Food Chem Toxicol; 2014 Aug; 70():9-18. PubMed ID: 24793377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
    Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non alcoholic fatty liver disease in a Nigerian population with type II diabetes mellitus.
    Olusanya TO; Lesi OA; Adeyomoye AA; Fasanmade OA
    Pan Afr Med J; 2016; 24():20. PubMed ID: 27583084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
    Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
    Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
    World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study.
    Tuttolomondo A; Petta S; Casuccio A; Maida C; Corte VD; Daidone M; Di Raimondo D; Pecoraro R; Fonte R; Cirrincione A; Zafonte R; Cabibi D; Cammà C; Di Marco V; Licata A; Magliozzo F; Marchesini G; Merlino G; Craxì A; Pinto A
    Cardiovasc Diabetol; 2018 Feb; 17(1):28. PubMed ID: 29452601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study.
    Dallio M; Masarone M; Caprio GG; Di Sarno R; Tuccillo C; Sasso FC; Persico M; Loguercio C; Federico A
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):261-268. PubMed ID: 28922438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Deretzi G; Zavos C; Mantzoros CS
    Curr Mol Med; 2012 Jan; 12(1):68-82. PubMed ID: 22082482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between exposures to brominated trihalomethanes, hepatic injury and type II diabetes mellitus.
    Makris KC; Andrianou XD; Charisiadis P; Burch JB; Seth RK; Ioannou A; Picolos M; Christophi CA; Chatterjee S
    Environ Int; 2016; 92-93():486-93. PubMed ID: 27173514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes.
    Guo K; Zhang L; Lu J; Yu H; Wu M; Bao Y; Chen H; Jia W
    J Diabetes Complications; 2017 Jan; 31(1):80-85. PubMed ID: 27742552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between urinary bisphenol A levels and nonalcoholic fatty liver disease in Korean adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017.
    An SJ; Yang EJ; Oh S; Park KJ; Kim T; Hong YP; Yang YJ
    Environ Health Prev Med; 2021 Sep; 26(1):91. PubMed ID: 34521354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.